معلومات عنا
HCPs
New Page
قصص المرضى
شارك
الصفحة الرئيسية
Who we are
What we do
Events
التشخيص المبكر
NICE
أشرطة فيديو
Copy of Reports
موارد
محل
اتصل بنا
Menu
Brigatinib is a 2nd generation TKI developed by Takeda. The recommended dose is 180mg taken daily. Along with Alectinib, Brigatinib is the usual first line treatment for newly diagnosed ALK-positive lung cancer patients